Premium
Juvenile bullous pemphigoid: the presentation and follow‐up of six cases
Author(s) -
GajicVeljic M,
Nikolic M,
Medenica L
Publication year - 2010
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/j.1468-3083.2009.03264.x
Subject(s) - medicine , retrospective cohort study , pediatrics , dapsone , bullous pemphigoid , population , dermatology , surgery , environmental health , antibody , immunology
Background Juvenile bullous pemphigoid (JBP) is a very rare autoimmune blistering disease. Up to now, 81 cases have been published. Objectives To describe clinical, histopathological and immunopathological characteristics of our patients with JBP, their response to therapy and clinical course, and to show the rarity of JBP in our population. Study design Retrospective study of all patients with JBP diagnosed from 1983 to the end of 2007. The patients were followed from 6 months to 24 years. Setting An academic, teaching hospital – Pediatric Dermatology Unit of the Institute of Dermatovenereology, Clinical Center of Serbia, Belgrade. Patients and methods Six patients with JBP (4 girls and 2 boys) aged 2 to 17 years. The average age at onset of BP was 10 years. The diagnosis was confirmed by histopathological analysis and direct immunofluorescence test. The patients were treated with systemic and topical corticosteroids, and three patients received dapsone. Results The disease control was achieved after 2 weeks to 2.5 months of therapy. The treatment lasted from 2 weeks to 4.5 months, 1.8 months at the average. The period from the beginning of the disease to complete remission ranged from 1.5 month to 5 years, with a mean value of 14 months. In one boy, the parents interrupted the therapy, and the disease remitted spontaneously after 5 years. Conclusion According to our experience, JBP can spontaneously remit within 5 years. JBP has a relatively indolent course and may be a self‐limiting disease. The patients should not be over‐treated in order to avoid side‐effects of medication.